Eli Lilly's Alimta approval

The FDA has approved a third indication for Eli Lilly's cancer drug, Alimta. The agency approved Altima for use in combination with cisplatin to treat patients with non-small cell lung cancer and will be a first-line treatment for patients with locally advanced and metastatic lung cancer with nonsquamous histology. The drug received approval earlier for patients to receive in combination with cisplatin in cases of malignant pleural mesothelioma and alone for in patients with locally-advanced or metastatic non-small cell lung cancer who had already had already undergone chemotherapy. Eli Lilly release

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.